Skip to content

Study · Case report or series · n = 1 · 2021

3 results

Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier.

Yonker LM, Gilboa T, Ogata AF, Senussi Y, Lazarovits R, Boribong BP, Bartsch YC, Loiselle M, Rivas MN, Porritt RA, Lima R, Davis JP and 21 more

Show all authors

Farkas EJ, Burns MD, Young N, Mahajan VS, Hajizadeh S, Lopez XIH, Kreuzer J, Morris R, Martinez EE, Han I, Griswold K Jr, Barry NC, Thompson DB, Church G, Edlow AG, Haas W, Pillai S, Arditi M, Alter G, Walt DR, Fasano A

The Journal of clinical investigation1 Jul 2021Cited by 218 (Europe PMC)

PMID34032635 (opens in a new tab)PMCIDPMC8279585 (opens in a new tab)DOI10.1172/jci149633 (opens in a new tab)PepBankPUB-34032635
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a patient with MIS-C, larazotide treatment coincided with decreased plasma SARS-CoV-2 spike antigen levels.

    In plain wordsIn a patient with MIS-C, larazotide treatment coincided with lower plasma spike antigen levels.

    Peptide
    Larazotide
    Outcome
    DecreasePlasma SARS-CoV-2 spike antigen
    Study

    n = 1

    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient with MIS-C treated with larazotide had a coinciding decrease in plasma SARS-CoV-2 spike antigen levels and inflammatory markers and a resultant clinical improvement above that achieved with currently available treatments.
  2. 02HumanCase report or seriesEfficacy outcome

    In a patient with MIS-C, larazotide treatment coincided with decreased inflammatory markers.

    In plain wordsIn a patient with MIS-C, larazotide treatment coincided with lower inflammatory markers.

    Peptide
    Larazotide
    Outcome
    DecreaseInflammatory markers
    Study

    n = 1

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient with MIS-C treated with larazotide had a coinciding decrease in plasma SARS-CoV-2 spike antigen levels and inflammatory markers and a resultant clinical improvement above that achieved with currently available treatments.
  3. 03HumanCase report or seriesEfficacy outcome

    A patient with MIS-C treated with larazotide showed clinical improvement beyond that achieved with currently available treatments.

    In plain wordsA patient with MIS-C treated with larazotide improved beyond the response achieved with currently available treatments.

    Peptide
    Larazotide
    Outcome
    IncreaseClinical improvement
    Study

    n = 1

    Comparator
    Currently available treatments
    Outcome group
    Overall treatment effect · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient with MIS-C treated with larazotide had a coinciding decrease in plasma SARS-CoV-2 spike antigen levels and inflammatory markers and a resultant clinical improvement above that achieved with currently available treatments.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.